The COVID-19 outbreak in dermatologic surgery: resetting clinical priorities

Editor

Emilia-Romagna was one of the Italian regions mostly affected by the COVID-19 pandemic, and lockdown measures were taken to slow the COVID-19 outbreak. All routine activities in Modena hospitals were suspended; however, urgent procedures were still to be performed. Setting the priority of procedures in oncological dermatology in the COVID-19 era is challenging.

We share our experience as a dermatological surgical unit at the Policlinico of Modena, highlighting the resetting of priorities and procedures, and the safety measures applied.

In 2019, 5483 surgical procedures were performed in our department: 482 inpatient, 836 day surgeries, and 4165

Figure 1 Reset of clinical priorities after the COVID-19 pandemic for dermatologic surgery planning. *SLB: sentinel node biopsy.
SAFETY PROCEDURES

INPATIENT

Phone triage by RN

Preadmission (7–10 days before surgery)

Blood test
SARS-CoV-2 IgG and IgM

Positive

Immediate oro-nasopharyngeal swab

Evaluation case by case risk/benefit balance

If possible, postpone

Negative

Proceed to oro-nasopharyngeal swab 24 hours before

Evaluation case by case risk/benefit balance

If possible, postpone

Chest x-ray

Self-isolation at home

Daily registration of:
– Temperature
– Cough (yes/no)

Nasopharyngeal swab

Positive

Evaluation case by case risk/benefit balance

If possible, postpone

Nasopharyngeal swab

Negative

Proceed

Evaluation case by case risk/benefit balance

If possible, postpone

Between preadmission and admission

Self-isolation at home

Daily registration of:
– Temperature
– Cough (yes/no)

Molecular test or oro-nasopharyngeal swab

Positive

If possible, postpone

Nasopharyngeal swab

Negative

Proceed

During surgery

PPE

If patient can wear mask during procedure

Nothing

If patient cannot wear mask during procedure: lesion located on nose, lip, cheek, ear, chin

Oro-nasopharyngeal swab

Positive

If possible, postpone

Oro-nasopharyngeal swab

Negative

Proceed

During surgery

PPE

When possible, only one patient/day who cannot wear the mask

PPE

If temperature, cough or any respiratory symptoms in 14 days

Postponed

If any contact with COVID-19-positive or suspicious for COVID-19-positive subject

Postponed

If no symptoms and no suspicion or no contact with COVID-19-positive subjects

Proceed

During surgery

1 patient every 45 minutes

PPE

Figure 2 Preoperative and operative procedures for hospital admission (inpatient and outpatient). PPE: personal protection equipment.
outpatients. Weekly, our surgical activity consists of (i) four sessions of major surgery for inpatient with anaesthesiologic support, 3 three patients/session; (ii) four day-surgery sessions, four patients/session; (iii) 13 sessions of outpatient surgeries.

After lockdown (9 March 2020), dermatology departments were challenged to a sudden reorganization of surgical activity within 48 h. We had to perform only undelayable urgent interventions, leading to a new definition of priorities (Fig. 1). We limited our activity to potentially life-threatening or severe cancer types, such as melanocytic lesions suspicious of thick melanoma, histologically confirmed thick melanoma, histologically confirmed infiltrating high-risk squamous cell carcinoma (SCC) according to NCCN guidelines and rapidly growing nodular lesions. All clinical charts were reviewed to assign these new priorities. We treated thick melanoma by performing both wide excision and sentinel node biopsy, while wide excision for in situ melanoma was deferred. Recently, different approaches were proposed regarding the possibility to postpone the node biopsy.6,8,9

Regarding SCC, the excision was performed in line with current guidelines while simple techniques, such as dermo-epidermal grafts, were selected for immediate reconstruction in order to shorten the hospitalization period. For in situ SCC and basal cell carcinoma (BCC), surgical treatment was postponed. Diagnostic incisional biopsies were restricted to severe diseases, such as suspicious blistering diseases or erythroderma.

Moreover, we set a new weekly plan of surgical sessions, consisting of (i) one session of major surgeries; (ii) two sessions of day surgeries; (iii) two sessions for outpatient surgeries; (iv) everyday, two urgent biopsies for in/outpatients.

All activities were performed wearing appropriate individual protective devices, such as FFP2 or FFP3 masks covered with a disposable surgical mask, protective eye-goggles or helmets, and overshoes in addition to the standard surgical equipment. Surgeons were requested to wear surgical equipment in a clean and safe area, different from the area they took off the equipment.

A strict triage procedure was applied before the admission of patients (Fig. 2). Consecutive surgical activities for outpatients were planned with a 45-min interval, to allow thorough cleaning of the operation room.

Dermatological surgery is considered a low-/medium-risk surgery. This also remains true in the current COVID-19 era, but only when the patient can safely wear a mask. For procedures on the face, we think that dermatological surgery should be considered as a high-risk procedure. Therefore, we suggest that independently from the type of anaesthesia used, it should be mandatory to wear high protection mask (FFP3) during surgery on the facial area. For body areas other than face, we suggest that FFP2 can be considered as an appropriate protection device.

We also believe that standardized consent forms should be prepared to inform patients of the inherent risk of getting infected from SARS-CoV-2 while they are in the hospital, in an effort to ensure transparency. Moreover, patients with dermatological conditions may feel abandoned, given the relocation of resources to address the pandemic emergency. It is therefore crucial to maintain proper communication with patients, ensuring that all urgent treatments continue to be delivered.

Conflicts of interest
None.

Acknowledgements
Editorial assistance was provided by Aashni Shah (Polistudium SRL, Milan, Italy) and was supported by internal funds.

E. Rossi,1,2 M. Trakatelli,2 L. Giacomelli,3,4 B. Ferrari,1 M. Francomano,1 G. Pellacani,1 C. Magnoni1

1Department of Dermatology, Head and Neck Skin Cancer Service, Modena and Reggio Emilia University, Modena, Italy, 2Second Department of Dermatology, Aristotle University Medical School, Papageorgiou General Hospital, Thessaloniki, Greece, 3Polistudium SRL, Milan, Italy, 4Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, Genoa, Italy

*Correspondence: E. Rossi. E-mail: dr.elenarossi@gmail.com

References
1. Government of Italy. Decree of the president of the Council of Ministers 9 March 2020. March 9, 2020. https://www.gazzettaufficiale.it/eli/id/2020/03/09/20A01358/sg (accessed 1 May 2020).
2. Government of Italy. Decree of the president of the Council of Ministers 11 March 2020. March 11, 2020. https://www.gazzettaufficiale.it/eli/id/2020/03/11/20A01605/sg (accessed 1 May 2020).
3. Government of Italy. Decree of the president of the Council of Ministers 10 April 2020. April 10, 2020. https://www.gazzettaufficiale.it/eli/id/2020/04/10/20A02179/sg (accessed 1 May 2020).
4. Price KN, Thiede R, Shi VY, Curiel-Lewandrowski C. Strategic dermatology clinical operations during COVID-19 pandemic. J Am Acad Dermatol 2020; Jun 82(6):e207–e209. doi:10.1016/j.jaad.2020.03.089
5. Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019-nCOV): Implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol 2020; May 34 (5):e213–e214. https://doi.org/10.1111/jdv.16386
6. Der Sarkissian SA, Kim L, Veness M, Yiiasemides E, Sebaratnam DF. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol 2020; Apr 10:S0190–9622(20)30610-1. https://doi.org/10.1016/j.jaad.2020.04.034
7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Squamous Cell Skin Cancer Version 1. www.nccn.org/professionals/physician_gls/pdf/squamous.pdf (accessed 1 May 2020).
8. Melanoma Institute Australia. Important notice regarding the management of clinically suspected primary melanoma during the COVID-19 crisis. https://micanusercontent.com/88a3bd328a963791aeb7c880/files/b833272a-052d-48b6-b62a-ea6bd82cbce60/Melanoma_Management__Covid_FINAL.pdf (accessed 1 May 2020).
9. Short-Term Recommendations for Cutaneous Melanoma Management During COVID-19 Pandemic. https://www.ncca.org/covid-19/pdf/Melanoma.pdf (accessed 1 May 2020).

DOI: 10.1111/jdv.16672